ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

 
Print Page
Email Article

FDA Approval Means Americans with Osteoarthritis Have a New Option

  [ 6 votes ]   [ Discuss This Article ]
By News Release • www.ProHealth.com • April 14, 2000


SUMMARY: New to U.S., Mobic, an osteoarthritis treatment, has successfully treated millions of patients in more than 100 countries.

RIDGEFIELD, CT (April 14, 2000) -- The U.S. Food and Drug Administration has approved Mobic (meloxicam) tablets for marketing as a treatment for osteoarthritis. This decision gives patients in the United States an alternative that has been used in millions of patients worldwide for relieving the pain and stiffness associated with the disease. As the population ages, the need for effective pain relief from osteoarthritis -- which currently affects 80 percent of Americans over age 65 -- is expected to increase. Millions of people are still searching for an effective treatment they can tolerate. For these patients, today's clearance of Mobic tablets for marketing in the U.S. provides an important new option.

Often, arthritis patients try several medications and find they are not effective or cause side effects that make tolerating the medication difficult. Some patients keep searching, while others simply give up. Mobic tablets provide a new alternative for patients -- when beginning therapy or when other treatments are discontinued.

"Osteoarthritis can be a very debilitating condition, often diminishing the quality of daily life for people who suffer from it," says Dr. David Yocum, director of the University of Arizona Arthritis Center. "Many of these patients cannot be successfully treated with current options, and even the newest choices do not work for everyone. Mobic tablets provide patients with a new alternative when other treatments are discontinued, whether due to lack of efficacy or side effects."

The safety and efficacy of Mobic tablets were established through clinical trials involving more than 22,000 patients both here and abroad. The majority of patients taking Mobic tablets experienced relief from their osteoarthritis symptoms with a low incidence of gastrointestinal side effects.

In the United States, Mobic tablets are indicated as a once-daily medication for relief of the signs and symptoms of osteoarthritis. As the third new non-steroidal anti-inflammatory drug (NSAID) introduced to the market in the past two years, Mobic is being priced approximately 20 percent less than Celebrex®* and Vioxx®** for the starting and maintenance daily dose of 7.5 mg.

Osteoarthritis -- a painful, debilitating disease that causes cartilage acting as a cushion in joints to break down -- is the most common form of arthritis, affecting primarily older Americans. More than $65 billion is spent each year on medical expenses and lost wages related to arthritis. ,
Like any medication, Mobic tablets are not appropriate for everyone. Patients who have a known allergy to meloxicam, aspirin or other traditional NSAIDs should not use Mobic tablets, nor should women who are, or may be, pregnant. Although use of Mobic tablets shows good gastrointestinal tolerability, gastrointestinal ulcers can develop without warning symptoms. Patients and physicians should remain alert to the earliest signs and symptoms of gastrointestinal bleeding.

Sources: Pharmaceuticals, Inc. and Abbott Laboratories.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12
Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery
Thyroid Health and Fibromyalgia Thyroid Health and Fibromyalgia
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map